Display options
Cite
Almubarak M, Newton M, Altaha R. Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan. J Oncol. 2008;2008:942618doi: 10.1155/2008/942618.
Almubarak, M., Newton, M., & Altaha, R. (2008). Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan. Journal of oncology, 2008942618. https://doi.org/10.1155/2008/942618
Almubarak, Mohammed, et al. "Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan." Journal of oncology vol. 2008 (2008): 942618. doi: https://doi.org/10.1155/2008/942618
Almubarak M, Newton M, Altaha R. Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan. J Oncol. 2008;2008:942618. doi: 10.1155/2008/942618. Epub 2008 Sep 02. PMID: 19259336; PMCID: PMC2648641.
Copy Download .nbib Format: NLM
Share it on

J Oncol. 2008;2008:942618. doi: 10.1155/2008/942618. Epub 2008 Sep 02.

Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan.

Journal of oncology

Mohammed Almubarak, Michael Newton, Ramin Altaha

Affiliations

  1. Section of Hematology/Oncology, Mary Babb Randolph Cancer Center, West Virginia University Hospital, Morgantown, WV 26506, USA.

PMID: 19259336 PMCID: PMC2648641 DOI: 10.1155/2008/942618

Abstract

Glioblastoma multiforme (GBM) carries a dismal prognosis despite the current standard of multimodality treatments. Recent studies showed promising results to a regimen consisting of a VEGF inhibitor, (bevacizumab) and a topoisomerase I inhibitor (irinotecan) [BI] in recurrent GBM. However, those patients with GBM who progress on BI will succumb to their disease generally in a very short period of time. We report a case of a 56-year-old male patient with GBM who declined surgical resection and received chemoradiation with temozolomide. This treatment was withheld secondary to significant thrombocytopenia. Subsequently, he achieved stable disease for 10 months with a regimen consisting of thalidomide and tamoxifen before progressing. This was followed by bevacizumab with irinotecan [BI], for which he had a significant partial response for 8 months with subsequent progression. Reinducing the patient with bevacizumab in combination with a pegylated liposomal doxorubicin [PLD] (a topoisomerase II inhibitor) demonstrated antitumor activity with significant shrinkage of contrast enhancing mass and peritumoral edema.

References

  1. Int J Nanomedicine. 2007;2(4):567-83 - PubMed
  2. Int J Cancer. 1993 Aug 19;55(1):115-21 - PubMed
  3. Cancer. 2001 Oct 1;92(7):1936-42 - PubMed
  4. Br J Cancer. 2000 Nov;83(10):1281-6 - PubMed
  5. Neuro Oncol. 2006 Apr;8(2):189-93 - PubMed
  6. Anticancer Res. 1999 Mar-Apr;19(2A):941-50 - PubMed
  7. J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6 - PubMed
  8. Expert Opin Investig Drugs. 2007 Dec;16(12):1895-908 - PubMed
  9. Neurology. 2006 Apr 25;66(8):1258-60 - PubMed
  10. Hematol Oncol Clin North Am. 1994 Apr;8(2):431-50 - PubMed
  11. Cancer Res. 1992 Jun 1;52(11):3241-5 - PubMed
  12. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  13. J Clin Oncol. 2007 Oct 20;25(30):4722-9 - PubMed
  14. Cancer. 2004 Mar 15;100(6):1199-207 - PubMed
  15. J Neurosurg. 1995 Dec;83(6):1029-37 - PubMed
  16. J Clin Oncol. 2007 Oct 20;25(30):4714-21 - PubMed
  17. Nat Med. 2001 Sep;7(9):987-9 - PubMed
  18. Cancer Res. 1981 Nov;41(11 Pt 1):4466-70 - PubMed
  19. Oncologist. 2006 Feb;11(2):152-64 - PubMed

Publication Types